Three new diabetes drugs approved in the US
The FDA has approved three new diabetes drugs – all from the same company. Analyst Søren Løntoft Hansen expalins the consequences it will have to Novo Nordisk.
by Stefan Singh Kailay
The Japanese company Takeda has had three new diabetes drugs – so-called DPP-4-inhibitors - approved for the US market.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
